Company profile
SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SAB-176 | phase2 | — | 2 | no active trials |
| SAB-185 | phase1 | — | 2 | completed, unknown |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06435936 | phase1 | active_not_recruiting | 2024-04-22 | 2025-02-01 | SAb Biotherapeutics, Inc. | A Study to Assess the Safety of SAB-176 to Prevent the Flu, Given IM in Healthy Adults Compared With Placebo |
| NCT07187531 | phase2 | recruiting | 2025-11-25 | 2027-11-01 | SAb Biotherapeutics, Inc. | SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes |
| NCT04471038 | phase1 | completed | 2020-07-29 | 2021-04-19 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-176 in Healthy Participants |
| NCT04469179 | phase1 | unknown | 2020-08-20 | 2021-02-25 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19 |
| NCT04468958 | phase1 | completed | 2020-07-01 | 2020-12-23 | SAb Biotherapeutics, Inc. | Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants |
FDA applications (0)
No records yet.